Substrate-Guided Design of Selective FXIIa Inhibitors Based on the Plant-Derived Momordica cochinchinensis Trypsin Inhibitor-II (MCoTI-II) Scaffold

Journal of Medicinal Chemistry

Volumn 59, Issue 15, 2016, Pages 7287-7292

  Swedberg, Joakim E ^a   Mahatmanto, Tunjung ^a   Abdul Ghani, Hafiza ^a   De Veer, Simon J ^b   Schroeder, Christina I ^a   Harris, Jonathan M ^b   Craik, David J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 12A INHIBITOR; BLOOD CLOTTING INHIBITOR; TRYPSIN INHIBITOR; TRYPSIN INHIBITOR II; UNCLASSIFIED DRUG; FACTOR XIIA INHIBITOR; OLIGOPEPTIDE; PLASMA PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; DRUG DESIGN; MOLECULAR DYNAMICS; MOMORDICA COCHINCHINENSIS; NONHUMAN; PEPTIDE LIBRARY; PROTEIN CLEAVAGE; PROTEIN SECONDARY STRUCTURE; SURFACE PROPERTY; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DOSE RESPONSE; HUMAN; METABOLISM; MOMORDICA; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

BLOOD PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; FACTOR XIIA; HUMANS; MOLECULAR DYNAMICS SIMULATION; MOMORDICA; OLIGOPEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84982085136     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00557     Document Type: Article

References (31)

1. Engelmann, B.; Massberg, S. Thrombosis as an intravascular effector of innate immunity Nat. Rev. Immunol. 2013, 13, 34-45 10.1038/nri3345
2. Mackman, N. Triggers, targets and treatments for thrombosis Nature 2008, 451, 914-918 10.1038/nature06797
3. Melnikova, I. The anticoagulants market Nat. Rev. Drug Discovery 2009, 8, 353-354 10.1038/nrd2851
4. Last, J. A. The missing link: the story of Karl Paul Link Toxicol. Sci. 2002, 66, 4-6 10.1093/toxsci/66.1.4
5. Wysowski, D. K.; Nourjah, P.; Swartz, L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action Arch. Intern. Med. 2007, 167, 1414-1419 10.1001/archinte.167.13.1414
6. Sun, W. Y.; Witte, D. P.; Degen, J. L.; Colbert, M. C.; Burkart, M. C.; Holmback, K.; Xiao, Q.; Bugge, T. H.; Degen, S. J. Prothrombin deficiency results in embryonic and neonatal lethality in mice Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 7597-7602 10.1073/pnas.95.13.7597
7. Dewerchin, M.; Liang, Z.; Moons, L.; Carmeliet, P.; Castellino, F. J.; Collen, D.; Rosen, E. D. Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice Thromb. Haemost. 2000, 83, 185-190
8. Bolton-Maggs, P. H.; Pasi, K. J. Haemophilias a and b Lancet 2003, 361, 1801-1809 10.1016/S0140-6736(03)13405-8
9. Dorgalaleh, A.; Hosseini, M. S.; Mobaraki, R. N.; Alizadeh, S.; Hosseini, S.; Tabibian, S.; Shamsizadeh, M.; Moghaddam, E. S.; Khosravi, S.; Rahimizadeh, A. Inhibition of factor XIIa, a new approach in management of thrombosis Ann. Transl. Med. 2015, 3, S20 10.3978/j.issn.2305-5839.2015.02.14
10. Seligsohn, U. Factor XI deficiency in humans J. Thromb. Haemostasis 2009, 7, 84-87 10.1111/j.1538-7836.2009.03395.x
11. Baeriswyl, V.; Calzavarini, S.; Chen, S.; Zorzi, A.; Bologna, L.; Angelillo-Scherrer, A.; Heinis, C. A synthetic factor XIIa inhibitor blocks selectively intrinsic coagulation initiation ACS Chem. Biol. 2015, 10, 1861-1870 10.1021/acschembio.5b00103
12. Larsson, M.; Rayzman, V.; Nolte, M. W.; Nickel, K. F.; Bjorkqvist, J.; Jamsa, A.; Hardy, M. P.; Fries, M.; Schmidbauer, S.; Hedenqvist, P.; Broome, M.; Pragst, I.; Dickneite, G.; Wilson, M. J.; Nash, A. D.; Panousis, C.; Renne, T. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk Sci. Transl. Med. 2014, 6, 222ra17 10.1126/scitranslmed.3006804
13. Frenzel, A.; Hust, M.; Schirrmann, T. Expression of recombinant antibodies Front. Immunol. 2013, 4, 217 10.3389/fimmu.2013.00217
14. Kenne, E.; Renne, T. Factor XII: a drug target for safe interference with thrombosis and inflammation Drug Discovery Today 2014, 19, 1459-1464 10.1016/j.drudis.2014.06.024
15. Kelly, C. A.; Laskowski, M., Jr.; Qasim, M. A. The role of scaffolding in standard mechanism serine proteinase inhibitors Protein Pept. Lett. 2005, 12, 465-471 10.2174/0929866054395383
16. Luckett, S.; Garcia, R. S.; Barker, J.; Konarev, A. V.; Shewry, P.; Clarke, A.; Brady, R. High-resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds J. Mol. Biol. 1999, 290, 525-533 10.1006/jmbi.1999.2891
17. Gray, K.; Elghadban, S.; Thongyoo, P.; Owen, K. A.; Szabo, R.; Bugge, T. H.; Tate, E. W.; Leatherbarrow, R. J.; Ellis, V. Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II Thromb. Haemostasis 2014, 112, 402-411 10.1160/TH13-11-0895
18. Thongyoo, P.; Bonomelli, C.; Leatherbarrow, R. J.; Tate, E. W. Potent inhibitors of beta-tryptase and human leukocyte elastase based on the MCoTI-II scaffold J. Med. Chem. 2009, 52, 6197-6200 10.1021/jm901233u
19. Mahatmanto, T. Review seed biopharmaceutical cyclic peptides: From discovery to applications Biopolymers 2015, 104, 804-814 10.1002/bip.22741
20. Hernandez, J. F.; Gagnon, J.; Chiche, L.; Nguyen, T. M.; Andrieu, J. P.; Heitz, A.; Trinh Hong, T.; Pham, T. T.; Le Nguyen, D. Squash trypsin inhibitors from Momordica cochinchinensis exhibit an atypical macrocyclic structure Biochemistry 2000, 39, 5722-5730 10.1021/bi9929756
21. Felizmenio-Quimio, M. E.; Daly, N. L.; Craik, D. J. Circular proteins in plants-solution structure of a novel macrocyclic trypsin inhibitor from Momordica cochinchinensis J. Biol. Chem. 2001, 276, 22875-22882 10.1074/jbc.M101666200
22. Chan, L. Y.; Gunasekera, S.; Henriques, S. T.; Worth, N. F.; Le, S. J.; Clark, R. J.; Campbell, J. H.; Craik, D. J.; Daly, N. L. Engineering pro-angiogenic peptides using stable, disulfide-rich cyclic scaffolds Blood 2011, 118, 6709-6717 10.1182/blood-2011-06-359141
23. Ji, Y.; Majumder, S.; Millard, M.; Borra, R.; Bi, T.; Elnagar, A. Y.; Neamati, N.; Shekhtman, A.; Camarero, J. A. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide J. Am. Chem. Soc. 2013, 135, 11623-11633 10.1021/ja405108p
24. Gosalia, D. N.; Salisbury, C. M.; Maly, D. J.; Ellman, J. A.; Diamond, S. L. Profiling serine protease substrate specificity with solution phase fluorogenic peptide microarrays Proteomics 2005, 5, 1292-1298 10.1002/pmic.200401011
25. Gosalia, D. N.; Salisbury, C. M.; Ellman, J. A.; Diamond, S. L. High throughput substrate specificity profiling of serine and cysteine proteases using solution-phase fluorogenic peptide microarrays Mol. Cell. Proteomics 2005, 4, 626-636 10.1074/mcp.M500004-MCP200
26. Hayashi, K.; Takehisa, T.; Hamato, N.; Takano, R.; Hara, S.; Miyata, T.; Kato, H. Inhibition of serine proteases of the blood coagulation system by squash family protease inhibitors J. Biochem. 1994, 116, 1013-1018
27. Craik, D. J.; Swedberg, J. E.; Mylne, J. S.; Cemazar, M. Cyclotides as a basis for drug design Expert Opin. Drug Discovery 2012, 7, 179-194 10.1517/17460441.2012.661554
28. de Veer, S. J.; Wang, C. K.; Harris, J. M.; Craik, D. J.; Swedberg, J. E. Improving the selectivity of engineered protease inhibitors: optimizing the P2 prime residue using a versatile cyclic peptide library J. Med. Chem. 2015, 58, 8257-8268 10.1021/acs.jmedchem.5b01148
29. Jones, P. M.; George, A. M. Computational analysis of the MCoTI-II plant defence knottin reveals a novel intermediate conformation that facilitates trypsin binding Sci. Rep. 2016, 6, 23174 10.1038/srep23174
30. Abbenante, G.; Leung, D.; Bond, T.; Fairlie, D. P. An efficient Fmoc strategy for the rapid synthesis of peptide para-nitroanilides Lett. Pept. Sci. 2000, 7, 347-351 10.1023/A:1013016323676
31. Swedberg, J. E.; Harris, J. M. Plasmin substrate binding site cooperativity guides the design of potent peptide aldehyde inhibitors Biochemistry 2011, 50, 8454-8462 10.1021/bi201203y